New hope for young adults with CML: asciminib under Real-World scrutiny

NCT ID NCT07681258

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study looks at how well the drug asciminib works and how safe it is for young adults with chronic myeloid leukemia (CML) in the Gulf region. Researchers will collect information from medical records of about 80 people aged 18 and older who have taken asciminib. The main goal is to see how many achieve a major molecular response, a key sign that the leukemia is well controlled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

asciminib

What this could lead to

If asciminib proves safe and effective in this younger population, it could offer a new treatment option for chronic myeloid leukemia.

What could go wrong

This is an observational study, not a controlled trial, so results may be less definitive. Side effects are possible, and the small sample size may limit generalizability.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact